Implementation of a ‘Worth to Society’ Reimbursement Model for Bilateral Orchiectomy for Hormonal Treatment of Prostate Cancer is Likely to Save Medicare $170 Million per Year if Surgeon’s Fee is Increased to $4500.00

Publisher： Karger

E-ISSN： 1661-7657|3|4|190-193

ISSN： 1661-7649

Source： Current Urology, Vol.3, Iss.4, 2009-12, pp. : 190-193

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neoadjuvant Hormonal Treatment and Radiotherapy for Prostate Cancer

By  

Oncology, Vol. 65, Iss. 1, 2003-09 ,pp. : 29-33

Karger

Access to resources Recommend Favorite

Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program

By  

Oncology, Vol. 65, Iss. 1, 2003-09 ,pp. : 1-4

Karger

Access to resources Recommend Favorite

Hormonal Predictors of Prostate Cancer

By  

Urologia Internationalis, Vol. 79, Iss. 1, 2007-07 ,pp. : 13-18

Karger

Access to resources Recommend Favorite

Early versus Deferred Hormonal Treatment for Asymptomatic Prostate Cancer

By  

Oncology Research and Treatment, Vol. 24, Iss. 3, 2001-07 ,pp. : 214-220

Karger

Access to resources Recommend Favorite

Trimodal Therapy for Inflammatory Breast Cancer: A Surgeon’s Perspective

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 3-12

Karger

Access to resources Recommend Favorite